Centiva Capital, LP Arcellx, Inc. Transaction History
Centiva Capital, LP
- $4.65 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding ACLX
# of Institutions
227Shares Held
45MCall Options Held
450KPut Options Held
647K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$279 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$224 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$222 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$212 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.79B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...